✦ LIBER ✦

PCN101 COST-UTILITY ANALYSIS OF DASATINIB AS A SECOND-LINE TREATMENT IN THE CHRONIC PHASE OF CHRONIC MYELOID LEUKAEMIA IN RUSSIA

✍ Scribed by S Kuznetzov; LJ Mungapen; Y Samyshkin; DE Jakouloff; U Sbarigia; M van Baardewijk

Book ID: 118614191
Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 76 KB
Volume: 13
Category: Article
ISSN: 1098-3015
DOI: 10.1016/s1098-3015(11)71996-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN47 COMPARISON OF HEALTH CARE RESOURCE

PCN47 COMPARISON OF HEALTH CARE RESOURCE UTILIZATION AND COSTS BETWEEN NILOTINIB AND DASATINIB AS SECOND LINE THERAPIES IN CHRONIC MYELOID LEUKEMIA (CML)

✍ EQ Wu; V Bollu; A Guo; A Guerin; M Tsaneva; D Williams; JD Griffin 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

PCN90 Cost Effectiveness Analysis of Ben

PCN90 Cost Effectiveness Analysis of Bendamustine as First Line Treatment for Chronic Lymphocytic Leukaemia in the Netherlands

✍ S. Vandekerckhove; K. Holtzer-Goor; D. Van Den Steen; Y. van Megen; P. Huijgens; 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

Cost–utility analysis of imatinib mesila

Cost–utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia

✍ Gordois, A; Scuffham, P; Warren, E; Ward, S 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 107 KB

PCN124 COST-UTILITY ANALYSIS OF DASATINI

PCN124 COST-UTILITY ANALYSIS OF DASATINIB IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA (CML) ON CHRONIC (CP), ACCELERATED (AP) AND BLAST (BP) PHASES IN BRAZIL

✍ E Asano; M Nita; A Moellmann-Coelho; R Rached; B Donato; E Rahal 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB

PCN30 A COST—UTILITY ANALYSIS MODEL FOR

PCN30 A COST—UTILITY ANALYSIS MODEL FOR THE SECOND LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN MEXICO

✍ I Contreras-Hernandez; J Mould-Quevedo; G Salinas-Escudero; J Tapia-Valencia; G 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB

Oral idarubicin in the treatment of acut

Oral idarubicin in the treatment of acute myelogenous leukaemia and the blast phase of chronic myeloid leukaemia

✍ S. T. A. Malik; J. Tucker; A. Z. S. Rohatiner; W. Brace; T. A. Lister 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 307 KB

Fourteen patients with poor-risk acute myelogenous leukaemia (AML) and five patients with accelerated phase/blast crisis chronic myeloid leukaemia (CML) were treated with 3 days of oral idarubicin (25 mg/m2/ day). No complete remissions or return to chronic phase CML were observed. A fall in the per